for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-AstraZeneca's Cancer Drug Fails To Meet Phase-II Goals In COVID-19 Trials

Nov 12 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA - CALAVI DID NOT MEET PRIMARY ENDPOINT OF INCREASING PROPORTION OF PATIENTS WHO REMAINED ALIVE AND FREE OF RESPIRATORY FAILURE

* ASTRAZENECA - ADDITION OF CALQUENCE TO BSC DID NOT INCREASE PROPORTION OF PATIENTS WHO REMAINED ALIVE AND FREE OF RESPIRATORY FAILURE

* ASTRAZENECA - RESULTS FROM CALAVI PHASE II TRIALS DO NOT IMPACT APPROVED INDICATIONS OR PENDING APPROVALS FOR CALQUENCE IN PATIENTS WITH BLOOD CANCERS.

* ASTRAZENECA - SAFETY AND TOLERABILITY PROFILES FOR CALQUENCE IN CALAVI PHASE II TRIALS WERE CONSISTENT WITH PREVIOUS TRIALS

* ASTRAZENECA - COMMITTED TO ADVANCING SCIENCE THAT HELPS PATIENTS DURING PANDEMIC, INCLUDING CLINICAL TRIALS FOR ASTRAZENECA OXFORD CORONAVIRUS VACCINE

* ASTRAZENECA - RESULTS FROM CALAVI PHASE II TRIALS DO NOT IMPACT APPROVED INDICATIONS OR PENDING APPROVALS FOR CALQUENCE IN PATIENTS WITH BLOOD CANCERS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up